Myelofibrosis Research Highlights from the 2024 ASH Conference

Out of the many myelofibrosis research publications presented at the 2024 ASH conference, read about some of the highlights. Stay tuned for coverage of these topics at HealthTree Conference Coverage in the coming weeks. 

New Myelofibrosis Treatments 

In a morning session hosted on Sunday, December 8th, titled “Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights, and Next-Gen Agents,” some of the topics about new myelofibrosis treatments included: 

• How effective and safe is fedratinib (Inrebic by BMS) for people with myelofibrosis who have low platelets?
• If you have previously relapsed or become refractory to a JAK inhibitor, how effective is the MDM2 inhibitor navtemadlin (by Kartos Therapeutics)?
• If ruxolitinib (Jakafi by Incyte) stops working, how effective is rovadicitinib (by ​​Chia Tai Tianqing Pharmaceutical)?
• How safe and effective is the next-generation JAK2/FLT3 inhibitor called flonoltinib maleate (by Chengdu Zenitar Biomedical Technology)? 

Advancements in Treating Myelofibrosis

In an evening session on Monday, December 9th, titled “Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care Innovative Therapies and Clinical Breakthroughs in Myelofibrosis," several of the topics included: 

• People with myelofibrosis experienced improved blood counts and other benefits when treated with elritercept (by Keros Therapeutics) by itself and in combination with ruxolitinib.
• Updates on the treatment combination of imetelstat (Rytelo by Geron) and ruxolitinib for people with intermediate and high-risk myelofibrosis.
• Treatment results of a pan-LOX inhibitor called pxs-5505 (by Syntara) with ruxolitinib.
• For people with myelofibrosis who have previously received treatment with ruxolitinib, specialists review how effective and safe the combination of selinexor (Xpovio by Karyopharm) and ruxolitinib is. 

Additional Popular Topics 

Other myelofibrosis research highlights from ASH 2024 that we'll write more about include:

• How effective a donor (allogeneic) stem cell transplant is for someone 70 years or older with myelofibrosis.
• Things that should be discussed to effectively personalize myelofibrosis treatment.
• How the myelofibrosis treatment ruxolitinib may affect patients’ anemia.
• People with myelofibrosis report how anemia and needing blood transfusions impact their quality of life.
• Early data reviewing how effective the treatments pacritinib or momelotinib may be. 

Stay Tuned! 

We’re excited to cover this important information on your behalf in the upcoming weeks, writing in a way that is easy to understand. Bookmark the link below to view the news about published conference coverage. 

HealthTree Conference Coverage

Sources: 

• Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents
• Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care Innovative Therapies and Clinical Breakthroughs in Myelofibrosis
• Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis
• Findings from a Longitudinal Series of Continuing Education and Quality Improvement Programs in Myelofibrosis
• Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
• Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis
• Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes